Pancreatic ductal adenocarcinoma (PDA) is the third-leading cause of cancer mortality in the US and is highly resistant to classical, targeted, and immune therapies. We show that human PDA cells are dependent on the provision of exogenous cystine to avert a catastrophic accumulation of lipid reactive oxygen species (ROS) that, left unchecked, leads to ferroptotic cell death, both in vitro and in vivo. Using a dual-recombinase genetically engineered model, we found that acute deletion of Slc7a11 led to tumorselective ferroptosis, tumor stabilizations/regressions, and extended overall survival. The mechanism of ferroptosis induction in PDA cells required the concerted depletion of both glutathione and coenzyme A, highlighting a novel branch of ferroptosis-relevant metabolism. Finally, we found that cystine depletion in vivo using the pre-IND agent cyst(e)inase phenocopied Slc7a11 deletion, inducing tumor-selective ferroptosis and disease stabilizations/regressions in the well-validated KPC model of PDA.
cystine, the dimeric, oxidized form of cysteine present in the extracellular environment. In four of five PDA cell lines, cystine withdrawal induced near-complete cell death within 24 hours and this was largely rescued by the lipophilic antioxidant Trolox (Figure 1A) . Dying, cystine-deprived cells underwent catastrophic destabilization of their plasma membranes, with no visual evidence of nuclear fragmentation (Supplementary Video 1).
Exogenous cystine is primarily imported by the cystine-glutamate antiporter, system x c - (11) , a heterodimer composed of a common subunit, SLC3A2 (4F2hc), and a specific subunit, SLC7A11 (xCT) (12) . We therefore assessed the effects of pharmacological inhibition of system x c using imidazole ketone erastin (IKE), a potent analog of the system x c inhibitor, erastin (13, 14) . The effects of system x c inhibition closely paralleled that of cystine withdrawal, with near-complete induction of cell death in the same four lines within 24 hours ( Figure 1B) . Cell death induced by system x C inhibition was rescued by Trolox ( Figure 1B) and appeared identical to that of cystine starvation, but distinct from staurosporine-induced apoptosis ( Supplementary Figure 1A; Supplementary Videos 2, 3) . Neither cystine withdrawal nor system x c inhibition (collectively referred to as "cysteine depletion") led to caspase 3 cleavage ( Supplementary Figure 1B) , indicating a form of non-apoptotic cell death.
The rapid, oxidative cell death resulting from cysteine depletion was reminiscent of ferroptosis, a form of iron-dependent, non-apoptotic cell death previously associated with erastin treatment (15) . Indeed, near-complete rescue of cysteine-depletion induced cell death was observed following co-treatment with either deferoxamine (DFO, an iron chelator) ferrostatin-1 (Fer1, a ferroptosis inhibitor) or N-acetyl cysteine (NAC, a cell permeable analog of cysteine). By contrast, the apoptosis inhibitor ZVAD-FMK had no effect, and inhibitors of necroptosis and autophagy offered only moderate rescue in a subset of lines, consistent with previous reports (16, 17) (Figure 1C, D, Supplementary Figure 1C -E).
Another defining feature of ferroptosis is the rapid accumulation of lipid ROS. Following cysteine depletion, we observed a sharp increase in oxidation of the sensor dye C11-BODIPY preceding the onset of cell death by at least an hour (Figure 1E, Supplementary Figure 2 ) and this was fully rescued by cotreatment with Trolox and other agents that rescued cysteine depletion-induced cell death (Figure 1E,F) .
By contrast, elevated general ROS from cysteine depletion was not rescued by Trolox, arguing against a more generalized oxidative response ( Figure 1G, H) . We conclude that cysteine depletion leads to the induction of ferroptosis in the majority of human PDA lines tested.
To assess the relevance of system x c to human patients, we examined the expression of the specific subunit SLC7A11 across six public PDA datasets that included matched normal tissues. A meta-analysis found a roughly 1.5-fold increase in SLC7A11 RNA expression in PDA vs. normal pancreas tissue (p= 4 .1 x 10 -7 , random effects model) (Supplementary Figure 3A) . Functionally, SLC7A11 expression in these cohorts was significantly associated with signatures of redox stress (Supplementary Figure 3B-D) .
Based on the predominant expression of SLC7A11 in the epithelium of PDA compared to stroma in laser capture microdissected human PDA samples (Supplementary Figure 4A ) (18) , these functions likely reflect its role in the malignant compartment.
Next, we examined expression data from The Cancer Genome Atlas (TCGA) and found that pancreatic tumors exhibit high absolute expression for SLC7A11 compared to other cancers, with comparatively low variance (Supplementary Figure 4B) . We also found that SLC7A11 expression was significantly upregulated relative to normal tissues in many tumor types ( Supplementary Figure 4C) .
Among those cancers with upregulation of SLC7A11, its expression was frequently associated with reduced overall survival (Supplementary Figure 4D) . SLC7A11 expression is therefore associated with malignancy, oxidative processes, and poor outcome across a wide range of human cancers.
To date, in vivo evidence for the role of system x c in cancer has largely relied on ex vivo assays, direct injection of chemical probes (19) , or implantation of cells with existing alterations that could impact engraftment (20) . In order to determine the reliance of established pancreatic tumors on system x c in a physiological context, we employed a dual recombinase genetic engineering strategy based on the wellvalidated "KPC" mouse (21 Figure 5 for more information) developed tumors histopathologically identical to those from KPC mice: typically a single, focal mass with moderate differentiation and robust stromal desmoplasia (Supplementary Figure 6A) , in the context of surrounding premalignant histopathology (Supplementary Figure 6B) . Following the identification of 4-7mm diameter pancreatic tumors by ultrasound, KPFSR mice were randomized to receive 6 daily doses of either vehicle or tamoxifen in order to induce genetic recombination to systemically delete both copies of Slc7a11. PCR performed on normal and tumor tissues confirmed at least partial recombination in vivo following tamoxifen delivery (Supplementary Figure 6C ). We found that acute deletion of Slc7a11 in tumor-bearing KPFSR mice nearly doubled median survival (Figure 2A , p< 0.0295, Log Rank) and a post-hoc analysis confirmed similar tumor sizes at enrollment (Supplementary Figure 6D) . Most tamoxifen-treated tumors exhibited a period of stable disease or regression whereas no such responses were observed in vehicle-treated animals (Figure 2B, Supplementary Figure 6E ). Critically, both the extension of overall survival and induction of tumor responses were completely reversed through the addition of NAC to the drinking water of tamoxifen-treated animals (Figures 2A,B ), confirming these phenotypes were related to cysteine metabolism. Modeling of tumor growth rates (22) showed that tamoxifen-treated tumors grew significantly slower than those in vehicle-treated mice (Supplementary Figure 6F) . Notably, one tumor regressed until it was undetectable by ultrasound ( Supplementary Figure 6G) ; this animal later succumbed to a new tumor arising in a different site in the pancreas. While some recombination was still evident in tumors at necropsy, Western blotting detected similar total levels of Slc7a11 protein in tamoxifen-and vehicletreated tumors at endpoint, suggesting the outgrowth of unrecombined tumor cells ( Supplementary   Figure 7A,B) .
Prior reports have relied on marker genes or metabolites extracted from tumor tissues to argue for the induction of in vivo ferroptosis (13, 19) . The absence of a histopathological characterization of tumor ferroptosis has hindered our ability to link individual markers to non-apoptotic cell death in a physiological (Figure 2I) , matching prior in vitro reports on the effects of ferroptosis on mitochondria (15, 23, 24) .
Finally, to directly compare the response of the Slc7a11-deleted tumors to the in vitro studies that have classically been used to define the phenomenon of ferroptosis, we performed laser capture microdissection and RNA-sequencing on malignant epithelial cells from KPFSR tumors treated with vehicle or tamoxifen. We found that genes that are differentially expressed in Slc7a11-deleted PDA cells in vivo are enriched for the ferroptosis signature defined from erastin-treated HT-1080 cells in vitro (25) , and vice versa (Figure 2J,K) . By contrast, none of the ten Gene Ontology (GO) apoptosis gene sets were enriched in tamoxifen-treated KPFSR tumors ( Supplementary Table 1 ). Taken together with our earlier findings, we conclude that the novel phenotype observed in tamoxifen-treated KPFSR tumors is a histologically identifiable in vivo manifestation of ferroptosis.
We next examined the mechanisms of ferroptosis in PDA cells (13, (26) (27) (28) . Prior studies have indicated that cysteine-depletion-induced ferroptosis occurs due to the loss of glutathione, which serves as a cofactor for the critical lipid peroxide detoxifying enzyme GPX4 (13, 29) . Consistent with this model, we observed a significant loss of intracellular cysteine and a near-complete loss of glutathione after 6 hours of IKE treatment in two human PDA lines (Figure 3A, Supplementary Figure 8A) . Figure 8D ) did not induce lipid ROS ( Figure 3E ) and had no impact on cell viability ( Figure 3F ). This result highlights contradictory findings regarding the sufficiency of glutathione depletion for the induction of ferroptosis in different cell lines (13, 30) . We inferred that in PDA cells, the loss of one or more additional cysteine-derived metabolites may be critical to the induction of ferroptosis.
To test this, we treated human PDA cells with 13 C-labelled cystine and examined the synthesis of cysteine-derived metabolites from exogenous cystine pools, before and after treatment with IKE. As expected, exogenous labelled cysteine was rapidly incorporated into glutathione pools and this flux was immediately inhibited by treatment with IKE ( Figure 3G) . By contrast, we did not detect significant contribution of exogenous cystine into taurine, lactate, citrate, or glutamate over the course of 24 hours (Supplementary Figure 8E) . We did, however, observe significant labelling of coenzyme A (CoA) pools ( Figure 3H) , an important cofactor that is synthesized from cysteine via the pantothenate pathway. CoA is a precursor to mevalonate, cholesterol, and coenzyme Q 10 (CoQ 10 ), among other metabolites, and is required for fatty acid synthesis, fatty acid β -oxidation, and many other critical metabolic processes.
Consistent with flux of cysteine into CoA, we found that inhibition of system x C reduced total CoA levels ( Figure 3I ) and simultaneously increased levels of pantothenate ( Figure 3J) Figure 3M) . We also found cell death was rescued by idebenone (a membrane permeable analog of CoQ 10 ) and by oleic acid, a monounsaturated fatty acid that lacks bisallylic sites that can initiate lipid peroxidation (19) . By contrast, a saturated fatty acid (palmitic) and a polyunsaturated fatty acid (linoleic) both failed to rescue ferroptosis (Supplementary Figure 9E,F) . Together, these data indicate that multiple cysteine-derived metabolites contribute to the regulation of ferroptosis, including both glutathione and Coenzyme A (Supplementary Figure 9G) .
Finally, we sought to leverage these findings as a means to selectively target pancreatic tumors for ferroptotic cell death. While potent system x C inhibitors are not yet ready for translation, an engineered enzyme, cyst(e)inase, was recently reported that effectively degrades both cystine and cysteine in mammalian circulation (33) . Cyst(e)inase is stable in mammals for days and is being developed clinically to treat the metabolic disorder cystinuria. We hypothesized that that cyst(e)inase could therapeutically recapitulate the effects of cystine starvation in PDA. In vitro, cyst(e)inase treatment reduced cell viability in all four sensitive PDA lines, albeit with slower kinetics than system x C inhibition (Figure 4A,   Supplementary Figure 10A ). The loss of viability was rescued by ferroptosis inhibitors Fer1 and DFO ( Figure 4B, Supplementary Figure 10B ). Treatment was also associated with induction of lipid oxidation, as measured by C11-BODIPY staining (Figure 4C, Supplementary Figure 10C ), leading to the conclusion that cyst(e)inase can induce ferroptosis in PDA cell lines.
To determine whether cyst(e)inase could induce ferroptosis in pancreatic tumors in vivo, we performed a short-term intervention study in KPC mice, a gold-standard genetically engineered model of PDA that is highly resistant to therapeutic intervention (21, 34) . Tumor-bearing KPC mice identified by ultrasound were treated for 10 days with either a low dose (50mg/kg, q3d, iv) or a high dose (100mg/kg, Figure 12B ). Normal tissues that were unaffected by pancreatic cancer in KPC mice showed no additional histopathology from cyst(e)inase-treatment. Thus we conclude that the therapeutic depletion of cysteine/cystine can lead to the selective induction of ferroptosis in Kras/p53 mutant autochthonous pancreatic ductal adenocarcinomas.
Since it was first described in 2012 (15) , ferroptosis has been investigated as a potential contributor to human pathology, notably neurodegenerative diseases, traumatic brain injury, acute kidney injury, and cancer (35) . However, in vivo evidence for ferroptosis has been limited as current ferroptosis-inducing agents have poor pharmacological properties and there are no established, specific markers of ferroptosis in vivo. Using both genetic and pharmacological models, we observed a novel histopathology in response to cysteine depletion in established Kras/p53 mutant pancreatic tumors, which we identified as an in vivo manifestation of ferroptosis.
All cells, whether normal or malignant, must carefully manage the disposition of atoms, energy, and electrons. Cancer cells selectively prioritize the production of biomass in support of persistent cell division, generally through pathways that incur an electron imbalance and thereby generate ROS (36) .
Cysteine-derived metabolites such as glutathione play a key role in managing electron imbalances that could otherwise lead to ferroptosis. However, GSH depletion alone is not sufficient to cause ferroptosis in PDA cells, implicating additional cysteine-derived metabolites in the management of ferroptosis. The identification of coenzyme A as a key downstream cysteine-derived metabolite that contributes to the control of ferroptosis provides a direct link to pathways that control the production, breakdown, and repair of lipid membrane components. While additional work will be necessary to illuminate precisely how CoAdependent processes contribute to suppression of ferroptosis, one potential model is that inhibition of GSH elevates the amount of cysteine available for the production of CoA, and by extension downstream metabolites that regulate detoxification of lipid ROS species. This model is strongly supported by the previous discovery of the ferroptosis inducer FIN56 (37) , which inhibits synthesis of mevalonate-derive products such as CoQ 10 , and the recent identification of a glutathione-independent suppressor of ferroptosis, FSP1, which catalyzes the reduction CoQ 10 to directly quench lipid peroxyl radicals (38, 39) .
Apoptosis is the predominant means by which many clinical anticancer agents are known to kill tumor cells. However, traditional chemotherapy has had limited efficacy in PDA and other forms of cell death
have not yet been leveraged as effectively in the clinic. The cancer-selective induction of ferroptosis following systemic deletion of Slc7a11 or cyst(e)inase treatment demonstrates the potential therapeutic utility of targeting cysteine metabolism. Cysteine depletion was remarkably well tolerated in non-tumor tissues. We speculate that this is due to the elevated ROS flux in KRAS-driven PDA cells, combined with the highly hypoxic microenvironment that arises in these poorly perfused-tumors (34) . The general tolerability of acute Slc7a11 deletion is consistent with prior reports that germline Slc7a11 knockout mice are viable and healthy into adulthood, though particularly sensitive to redox stress (40) , and cyst(e)inase was previously shown to be well tolerated in healthy mammals (33) . Combined with evidence that this pathway is upregulated across human cancers, we consider cysteine metabolism to be a strong target for clinical development, both for PDA and possibly other malignancies. Taken together, our results underscore an emerging understanding that maintenance of intracellular redox state is critical to cancer cell viability and may be targeted as form of metabolic anticancer therapy.
Materials and Methods Cell lines, cell culture, and viability assays
All cell lines were obtained from ATCC and tested negatively for mycoplasma infection. 
Flow cytometric detection of ROS
Cell lines were plated in quadruplicate at the cell numbers indicated previously in a 96-well plate format.
Cells were allowed to seed overnight and were subjected to various compound treatments for indicated times. Cells were then incubated for 30 minutes in live-cell imaging solution containing the pertinent ROS dye at the following concentrations: C-11 BODIPY, 2 µM; and H2DCFDA, 10 µM (Invitrogen, C6827).
Cells were then washed with PBS, trypsinized with .25% trypsin (Life Technologies, 25200-056), and neutralized with 10% FBS in PBS at a 1:1 volume. Cells were strained through a 40μM strainer (BD Falcon, 08-771-1), and analyzed on a MACSQuant Analyzer 10, BD LSRII, or a BD Fortessa with high throughput attachment depending on the application. A minimum of 4,000 cells were analyzed per condition. For both C-11 BODIPY and H2DCFDA, signal was analyzed in the FITC channel. Software analysis was carried out using FlowJo V10. tubes. Cells were heated to indicated temperatures for 3 minutes in two batches in a preheated thermocycler, then placed at room temperature for three minutes, then snap frozen in liquid nitrogen.
Cell-based Thermal Shift Assay
Samples were placed into the PCR machine only when it reached the desired temp, and heated for three minutes, following by three minutes at RT. Cells were lysed via two freeze-thaw cycles of liquid nitrogen/25°C, vortexed, and then spun at 20,000 rpm for 20 min at 4°C. Supernatant was removed, sample buffer added, and samples boiled heated to 70°C for 10 min, and then loaded for gel electrophoresis at 200V for 45min. Western blotting for PANK1 was performed according to standard protocols. phenol red free 0.5% trypsin (Life Technologies, 25200-056), and neutralized with 10% FBS in PBS at a 1:1 volume. Cells were strained through a 40μM strainer (BD Falcon, 08-771-1), and analyzed a BD Fortessa. A minimum of 10,000 cells were analyzed per condition using FITC channel. Software analysis was carried out using FlowJo V10.
Cyst(e)inase in vitro studies

Mass Spectrometry-Based Metabolomics
Unlabeled targeted metabolomics (For IKE and PANK inhibitor PD markers)
Cells were plated at 0.5 million cells per well in 6-well plates and treated with the indicated conditions.
Following treatment, the medium was aspirated and cells were lysed using cold 80% methanol and extracts were incubated in -80ºC for 10 min and centrifugation at 14,000 rpm for 10 min at 4°C. 
Metabolomics Data Analysis (For IKE and PANK inhibitor PD markers)
Raw data were pre-processed with Agilent MassHunter Workstation Software Quantitative QqQ Analysis The QqQ data pre-processed with Agilent MassHunter Workstation Software Quantitative QqQ Analysis Software (B0700). Additional analyses were post-processed for further quality control in the programming language R. We calculated coefficient of variation (CV) across replicate samples for each metabolite given a cut-off value of peak areas in both the positive and the negative modes. We then compared distributions of CVs for the whole dataset for a set of peak area cut-off values of 0, 1000, 5000, 10000, 15000, 20000, 25000 and 30000 in each mode. A noise cut-off value of peak areas in each mode was chosen by manual inspection of the CV distributions. Each sample is then normalized by the total intensity of all metabolites to reflect the same protein content as a normalization factor. We then retained only those metabolites with at least 2 replicate measurements. The remaining missing value in each condition for each metabolite was filled with the mean value of the other replicate measurements. All other bioinformatics analyses including graphs and plots were done using R/Bioconductor.
Laser capture microdissection and RNA sequencing
Cryosections of OCT-embedded tissue blocks from KPFSR mice treated with corn oil and tamoxifen, respectively, were transferred to PEN membrane glass slides and stained with cresyl violet acetate. on the entire in vitro and in vivo differential gene expression signature, respectively, was carried out as described previously (42) .
Microarray data. Gene expression data from studies comparing pancreatic ductal adenocarcinoma specimen with normal pancreas parenchyma were downloaded from the Gene Expression Omnibus 
Differential gene expression analysis
Genome-wide differential gene expression analysis normal tissue of origin and tumor tissue were calculated using the limma (55) R package using (gc)rma-normalized expression data for microarray studies and log 2 -transformed normalized count data for the TCGA cohorts. If normal and tumor samples were matched, i.e. from the same patient, a paired design was specified in the design formula.
Gene set enrichment analysis
In order to examine the relationship of pathway activity and SLC7A11 expression, we used the R implementation of single sample Gene Set Enrichment analysis: GSVA (gene set variation analysis) with default parameters (56) after pre-filtering each expression matrix for genes with an interquartile range > 0.5. PDA tumors from the following cohorts were examined: TCGA, ICGC RNA-Seq, ICGC microarray, NIH, UNC and Collisson their enrichment score per sample was calculated for the following gene sets from the MSigDB (v.6.0) (57): HALLMARK_REACTIVE_OXIGEN_SPECIES, SINGH_NFELE2_TARGETS and GO_CELL_REDOX_HOMEOSTASIS.
Effect size meta-analysis
Log 2 fold change. The effect size (i.e. log 2 fold change) and its standard error for SLC7A11 were extracted from the respective genome-wide differential expression analysis of 6 studies where global expression in normal pancreatic tissue was compared to PDA.
Pearson correlation. Pearson correlation and its standard error were calculated for each study and gene set, respectively, between the gene set enrichment scores per sample and the median-centered SLC7A11 expression per sample using the cor.test function from the stats R package.
Meta-analysis for each metric was carried out using the metafor (58) R package. Both random and fixed effect models were fit using the rma function (method = "REML" and method = "FE", respectively).
Survival analysis.
The association of SLC7A11 expression status with disease outcome was evaluated using a log-rank test as implemented in the survdiff function from the survival (59) R package. Patients were grouped into tertiles according to normalized SLC7A11 expression and differences in outcome were assessed between the upper and lower tertile.
Animal Breeding and genotyping
All studies were carried out in accordance with the relevant institutional guidelines of Columbia University.
Generation of Pdx1-FlpO mice
The 
Generation of Slc7a11 conditional knockout mice
Genotyping
Genotyping was carried out using protocols provided by Jackson Laboratory for all strains obtained from this vendor. Slc7a11 Fl/Fl genotyping was carried out as follows:
Forward primer: 5'-tgggttggtctctggtgatc-3'; Reverse primer: 5'-cctgtgaagatccgcctact-3'
Cycling conditions: 1. 94ºC 3 minutes; 2. 94ºC 1 minute; 3. 60ºC 2 minutes; 4. 72ºC 1 minute; Cycle to step 2, 29 times.; 5. 72ºC 5 minutes; 6. 4ºC forever
Expected amplicons: Slc7a11
Fl/Fl mice: 386 bp; WT mice: no amplicon Slc7a11 recombinatorial genotyping was custom designed as follows:
Forward primer: 5'-tgg gtt ggt ctc tgg tga tc-3'; Reverse primer: 5'-ctt aac ccc agc acc att cg-3'
Cycling conditions: 1. 95ºC 2 min; 2. 95ºC 1 min; 3. 56ºC 30 seconds; 4. 72ºC 1 min; Cycle to step 2, 34 times; 5. 72ºC 5 min; 6. 4ºC forever
Fl/Fl unrecombined = 1285 bp; Slc7a11 Fl/Fl recombined = 450 bp; WT mouse = 1240 bp.
Western blot
Western blot for Slc7a11 was carried out using standard protocols. In short, cultured MEFs were collected in PBS and lysed with Flag lysis buffer. Tumor samples were ground and lysed in Flag lysis buffer, and proteins were quantified with Bradford assay. Proteins were run on an SDS PAGE gel under denaturing conditions, transferred to a membrane, and probed with primary antibody (Cell Signaling, s12691) overnight at 4ºC. Blot was probed with an appropriate secondary and developed using a standard ECL kit.
Survival study
At approximately 42 days of age, KPSFR mice were treated with cerulein (Sigma, C9026) at 250 µg/kg by intraperitoneal injection for 5 consecutive days to induce chronic pancreatitis and accelerate tumor formation, as per previous reports (60) (61) (62) . Tumor formation was monitored initially by once weekly palpation and upon positive palpation, by twice-weekly ultrasound. Once the average diameter of tumors of the pancreas was 4-7 mm in size, mice were randomly enrolled into the survival study. Mice were treated with either corn oil (Sigma, C8267) or tamoxifen (Sigma, T5648) at 200 mg/kg by oral gavage for 6 consecutive days. Afterwards, a small cohort of mice was enrolled on a tamoxifen and NAC combination treatment. These mice were administered tamoxifen in the aforementioned fashion and administered NAC in their drinking water at 1 g/L. Subsequently, small cohorts of KPC mice were enrolled in a vehicle treatment arm and on an NAC only treatment arm, as controls. Mice were euthanized once they reached endpoint criteria consisting of a combined physical and behavioral metric designed to identify mice prior to death. Tumor samples were either fixed in formalin overnight at 4ºC, fixed in PFA at 4ºC overnight followed by sucrose-mediated water displacement for 24 hours at 4ºC, frozen in OCT, or flash frozen in liquid nitrogen.
Ultrasound
Tumor ultrasonography and volume quantification was carried out as previously described (63) .
Pathology and immunohistochemistry
Samples that had been fixed in formalin were washed in 70% ethanol and subjected to standard dehydration processing to prepare them for mounting in paraffin wax blocks. Paraffin blocks were sectioned on a Leica RM 2235 at 5 µM thickness. The sections were mounted on charged slides and heated to 60ºC to melt wax and ensure tissue adherence to the slide. Slides were then subjected to standard rehydration and antigen retrieval was carried out for five minutes in boiling 10 mM sodium citrate buffer pH 6, .05% Tween-20 using a pressure cooker. Slides were allowed to cool to room temperature in an ice-cold water bath. Slides were then incubated in 3% hydrogen peroxide for 20 minutes at room temperature to block endogenous peroxidases. Slides were blocked in 1.5% horse serum and 2% animal free blocker (Vector Laboratories, SP-5030) for 1 hour at room temperature. Malondialdehyde-stained slides however were blocked in 5% BSA. Slides were then stained with the appropriate antibody: Cleaved TEM operated at 120 kV using Zeemas acquisition system with 2K of resolution.
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